Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Specific CD8 T-cell responses to human immunodeficiency virus type 1 (HIV-1) are induced in primary infection and make an important contribution to the control of early viral replication. The importance of neutralizing antibodies in containing primary viremia is questioned because they usually arise much later. Nevertheless antienvelope antibodies develop simultaneously with, or even before, peak viremia. We determined whether such antibodies might control viremia by complement-mediated inactivation (CMI). In each of seven patients studied, antibodies capable of CMI appeared at or shortly after the peak in viremia, concomitantly with detection of virus-specific T-cell responses. The CMI was effective on both autologous and heterologous HIV-1 isolates. Activation of the classical pathway and direct viral lysis were at least partly responsible. Since immunoglobulin G (IgG)-antibodies triggered the CMI, specific memory B cells could also be induced by vaccination. Thus, consideration should be given to vaccination strategies that induce IgG antibodies capable of CMI.

Original publication

DOI

10.1128/JVI.79.5.2823-2830.2005

Type

Journal article

Journal

J Virol

Publication Date

03/2005

Volume

79

Pages

2823 - 2830

Keywords

Adult, Antibody-Dependent Cell Cytotoxicity, Complement System Proteins, Gene Products, env, HIV Antibodies, HIV Infections, HIV-1, Humans, Immunoglobulin G, Male, Neutralization Tests, T-Lymphocytes, Time Factors, Viremia